Vident Investment Advisory LLC Takes $496,000 Position in Boston Scientific Co. (BSX)

Vident Investment Advisory LLC purchased a new stake in Boston Scientific Co. (NYSE:BSX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 20,007 shares of the medical equipment provider’s stock, valued at approximately $496,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Bollard Group LLC boosted its stake in shares of Boston Scientific by 0.3% in the 4th quarter. Bollard Group LLC now owns 33,854,117 shares of the medical equipment provider’s stock valued at $839,244,000 after purchasing an additional 118,050 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Boston Scientific by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 13,040,987 shares of the medical equipment provider’s stock valued at $322,533,000 after purchasing an additional 373,607 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Boston Scientific by 29.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,945,671 shares of the medical equipment provider’s stock valued at $296,133,000 after purchasing an additional 2,705,194 shares in the last quarter. OppenheimerFunds Inc. boosted its stake in shares of Boston Scientific by 11.5% in the 4th quarter. OppenheimerFunds Inc. now owns 7,976,540 shares of the medical equipment provider’s stock valued at $197,739,000 after purchasing an additional 824,195 shares in the last quarter. Finally, Boston Partners boosted its stake in shares of Boston Scientific by 3.8% in the 4th quarter. Boston Partners now owns 7,475,797 shares of the medical equipment provider’s stock valued at $185,325,000 after purchasing an additional 276,390 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of research firms have recently weighed in on BSX. Barclays restated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a research note on Wednesday, January 10th. Needham & Company LLC upgraded shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and raised their price target for the company from $25.04 to $32.00 in a research note on Friday, December 8th. BMO Capital Markets restated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a research note on Wednesday, November 29th. Oppenheimer restated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. Finally, Canaccord Genuity cut their target price on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.16.

Boston Scientific Co. (NYSE:BSX) opened at $26.30 on Monday. The company has a current ratio of 0.68, a quick ratio of 0.49 and a debt-to-equity ratio of 0.54. Boston Scientific Co. has a fifty-two week low of $24.12 and a fifty-two week high of $29.93. The stock has a market cap of $36,160.16, a P/E ratio of 375.71, a price-to-earnings-growth ratio of 1.90 and a beta of 0.82.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same quarter last year, the business earned $0.30 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. sell-side analysts forecast that Boston Scientific Co. will post 1.37 earnings per share for the current year.

In other Boston Scientific news, SVP John Bradley Sorenson sold 2,200 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $27.63, for a total transaction of $60,786.00. Following the completion of the transaction, the senior vice president now owns 34,636 shares in the company, valued at approximately $956,992.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael P. Phalen sold 15,835 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 279,488 shares of company stock valued at $7,543,456. Company insiders own 0.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Vident Investment Advisory LLC Takes $496,000 Position in Boston Scientific Co. (BSX)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3301730/vident-investment-advisory-llc-takes-496000-position-in-boston-scientific-co-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: National Bankshares, Inc.  Given Average Rating of “Strong Buy” by Brokerages
Zacks: National Bankshares, Inc. Given Average Rating of “Strong Buy” by Brokerages
Zacks: Analysts Anticipate The Bank of New York Mellon  Will Post Earnings of $1.02 Per Share
Zacks: Analysts Anticipate The Bank of New York Mellon Will Post Earnings of $1.02 Per Share
Bankcoin 24 Hour Volume Hits $0.00
Bankcoin 24 Hour Volume Hits $0.00
Elementrem  Trading 1.4% Lower  This Week
Elementrem Trading 1.4% Lower This Week
Fastcoin Trading 1% Higher  Over Last Week
Fastcoin Trading 1% Higher Over Last Week
Kadant  Expected to Post Quarterly Sales of $145.40 Million
Kadant Expected to Post Quarterly Sales of $145.40 Million


© 2006-2018 Ticker Report. Google+.